Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Your view on SFOSF
Overview
What the company does, where it operates, and who runs it.
About Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Yi Liu
- Headquarters
- Building A, Shanghai, CN
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Yi Liu
- Headquarters
- Building A, Shanghai, CN
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments.
The company offers pharmaceutical products in the areas of tumor, immune modulation, metabolism, alimentary and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services. Further, it engages in retail and wholesale distribution of medicines.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and the rating behind it. SFOSF last traded at $2.61, 16.9× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.. Starting points for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: P/E 16.9, EPS $1.28, beta 0.73 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.. Trailing twelve-month EPS for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. stands at $1.28. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. valued side by side against its closest peers. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and how their positions are changing. At a $6.92B market value, institutional positions materially move Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. executives and directors. Shares of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. have traded between $1.62 and $3.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Shanghai Fosun Pharmaceutical (Group) Co., Ltd.. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a $6.92B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Shanghai Fosun Pharmaceutical (Group) Co., Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.. Coverage tracks Shanghai Fosun Pharmaceutical (Group) Co., Ltd. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.